Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines - King, Laura M.; Lewnard, Joseph A. (Vaccine, 2024)
Keywords: Adolescent; Adult; Adults; Age groups; Aged; Aged, 80 and over; Allergy and Immunology; Antibiotics; Caregivers; Child; Child, Preschool; Clinical trials; Conjugates; Cost of Illness; Costs; death; Economics; Estimates; Etiology; Female; GDP; Gross Domestic Product; Health economics; Hospitalization; Human subjects; Humans; Incidence; Infant; Invasive pneumococcal disease; Male; Meningitis; Middle Aged; monitoring; otitis; Otitis media; Otitis Media - economics; Otitis Media - epidemiology; Otitis Media - microbiology; Otitis Media - prevention & control; Pediatrics; Pneumococcal conjugate vaccine; Pneumococcal Infections - economics; Pneumococcal Infections - epidemiology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - economics; Pneumococcal Vaccines - immunology; Pneumonia; Prescriptions; Quality-Adjusted Life Years; Random variables; Respiratory tract infection; Respiratory Tract Infections - economics; Respiratory Tract Infections - epidemiology; Respiratory Tract Infections - prevention & control; Serogroup; Serotypes; Sinusitis; Streptococcus infections; Streptococcus pneumoniae; Streptococcus pneumoniae - classification; Streptococcus pneumoniae - immunology; United States - epidemiology; Vaccines; Vaccines, Conjugate - economics; Vaccines, Conjugate - immunology; Young Adult; United States; United States--US; Pneumococcal conjugate vaccine; Invasive pneumococcal disease; Pneumonia; Health economics